Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Share-based Compensation (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Share-based Compensation readings, the most recent being $21.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Share-based Compensation fell 19.26% year-over-year to $21.2 million, compared with a TTM value of $104.0 million through Dec 2025, down 8.87%, and an annual FY2025 reading of $104.0 million, down 8.87% over the prior year.
  • Share-based Compensation hit $21.2 million in Q4 2025 for Apellis Pharmaceuticals, down from $28.2 million in the prior quarter.
  • The five-year high for Share-based Compensation was $30.3 million in Q1 2024, with the low at $16.4 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $25.2 million (2022), compared with a mean of $24.3 million.
  • The sharpest move saw Share-based Compensation skyrocketed 76.88% in 2021, then decreased 19.26% in 2025.
  • Year by year, Share-based Compensation stood at $19.3 million in 2021, then increased by 25.52% to $24.2 million in 2022, then rose by 8.16% to $26.2 million in 2023, then rose by 0.36% to $26.3 million in 2024, then dropped by 19.26% to $21.2 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $21.2 million, $28.2 million, and $27.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.